US Senate finance panel clears healthcare reform bill with new pharma fees
This article was originally published in Scrip
Executive Summary
In a 14 to nine vote largely along party lines, the US Senate finance committee passed its version of healthcare reform legislation that would halve the out-of-pocket price of innovative medicines in the Medicare Part D coverage gap, increase the minimum Medicaid rebates for branded and generic drugs and require the branded drug industry to pay a total of $2.3 billion in new annual fees.